Nottingham Advisors Inc. Has $319,000 Stake in SPDR S&P Biotech ETF (NYSEARCA:XBI)

Nottingham Advisors Inc. decreased its holdings in shares of SPDR S&P Biotech ETF (NYSEARCA:XBI) by 20.3% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 2,355 shares of the exchange traded fund’s stock after selling 600 shares during the quarter. Nottingham Advisors Inc.’s holdings in SPDR S&P Biotech ETF were worth $319,000 at the end of the most recent quarter.

A number of other hedge funds and other institutional investors have also modified their holdings of the business. JPMorgan Chase & Co. raised its stake in SPDR S&P Biotech ETF by 602.2% during the first quarter. JPMorgan Chase & Co. now owns 6,792,579 shares of the exchange traded fund’s stock worth $921,413,000 after acquiring an additional 5,825,292 shares in the last quarter. Toronto Dominion Bank raised its stake in SPDR S&P Biotech ETF by 1,634,566.7% during the second quarter. Toronto Dominion Bank now owns 6,375,200 shares of the exchange traded fund’s stock worth $864,075,000 after acquiring an additional 6,374,810 shares in the last quarter. SG Americas Securities LLC raised its stake in SPDR S&P Biotech ETF by 111.8% during the first quarter. SG Americas Securities LLC now owns 510,496 shares of the exchange traded fund’s stock worth $69,249,000 after acquiring an additional 4,819,091 shares in the last quarter. Bank Julius Baer & Co. Ltd Zurich raised its stake in SPDR S&P Biotech ETF by 20.0% during the first quarter. Bank Julius Baer & Co. Ltd Zurich now owns 361,667 shares of the exchange traded fund’s stock worth $49,060,000 after acquiring an additional 60,396 shares in the last quarter. Finally, Royal Bank of Canada raised its stake in SPDR S&P Biotech ETF by 131.4% during the first quarter. Royal Bank of Canada now owns 359,751 shares of the exchange traded fund’s stock worth $48,802,000 after acquiring an additional 1,503,821 shares in the last quarter.

NYSEARCA XBI traded up $1.46 during trading on Wednesday, hitting $130.45. 207,666 shares of the company’s stock were exchanged, compared to its average volume of 6,145,633. The stock’s 50 day moving average price is $128.18 and its two-hundred day moving average price is $131.92. SPDR S&P Biotech ETF has a fifty-two week low of $105.89 and a fifty-two week high of $174.79.

SPDR S&P Biotech ETF Company Profile

SPDR S&P Biotech ETF (the Fund) seeks to closely match the returns and characteristics of the S&P Biotechnology Select Industry Index. The S&P Biotechnology Select Industry Index represents the biotechnology sub-industry portion of the S&P Total Markets Index. The S&P TMI tracks all the United States common stocks listed on the New York Stock Exchange, American Stock Exchange, National Association of Securities Dealers Automated Quotation (NASDAQ) National Market and NASDAQ Small Cap exchanges.

Featured Story: Example of operating income, EBIT and EBITDA

Want to see what other hedge funds are holding XBI? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for SPDR S&P Biotech ETF (NYSEARCA:XBI).

Institutional Ownership by Quarter for SPDR S&P Biotech ETF (NYSEARCA:XBI)

Receive News & Ratings for SPDR S&P Biotech ETF Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for SPDR S&P Biotech ETF and related companies with MarketBeat.com's FREE daily email newsletter.